After verifying that organ transplant rejection corresponds to a rise in cell-free donor DNA in recipient blood samples, researchers from Stanford University developed a sequencing-based approach for assessing these donor DNA levels.
The test, from researchers at the Cyprus Institute of Neurology and Genetics, combines methylated DNA immunoprecipitation and quantitative real-time PCR, and has demonstrated 100 percent sensitivity and specificity.
Through genome comparisons and follow-up studies using mouse embryos and human cells, Stanford University researchers have gathered evidence that some human-specific traits may result from a loss of regulatory DNA.
The decision means that "Aetna has decided to pay for AlloMap as a matter of policy," an XDx spokesperson said. Prior to the policy decision, "Aetna would require medical justification for each test to consider whether or not to pay" for it.